risperidone has been researched along with Catatonic Rigidity in 9 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Over 3 months, 41 patients with schizophrenia were randomized to treatment with risperidone 1-12 mg (n=21) or haloperidol 2-20 mg (n=20) daily." | 9.11 | Adverse effects of risperidone and haloperidol treatment in schizophrenia. ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| " In the USA, dosing tends to be expressed in mg] or oral risperidone [during initiation of risperidone long-acting injection (RLAI) days 1-28] and biweekly flexible-dose RLAI (n=173; initial injection day 8)." | 6.79 | Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. ( Alphs, L; Bossie, CA; Fu, DJ; Ma, YW; Sliwa, JK, 2014) |
| "Over 3 months, 41 patients with schizophrenia were randomized to treatment with risperidone 1-12 mg (n=21) or haloperidol 2-20 mg (n=20) daily." | 5.11 | Adverse effects of risperidone and haloperidol treatment in schizophrenia. ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| " In the USA, dosing tends to be expressed in mg] or oral risperidone [during initiation of risperidone long-acting injection (RLAI) days 1-28] and biweekly flexible-dose RLAI (n=173; initial injection day 8)." | 2.79 | Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. ( Alphs, L; Bossie, CA; Fu, DJ; Ma, YW; Sliwa, JK, 2014) |
| " The diagnosis of rhabdomyolysis was confirmed by myoglobinemia dosage and ortholuidine test." | 1.32 | [Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment]. ( Busiello, L; Cascella, M; De Robertis, E; Di Domenico, MG; Palmese, S; Pezza, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, DJ | 1 |
| Bossie, CA | 1 |
| Sliwa, JK | 1 |
| Ma, YW | 1 |
| Alphs, L | 1 |
| Stocker, L | 1 |
| Jellestad, L | 1 |
| Jenewein, J | 1 |
| Boettger, S | 1 |
| Lamkin, S | 1 |
| Buhl, D | 1 |
| Pezza, M | 1 |
| Busiello, L | 1 |
| Palmese, S | 1 |
| Cascella, M | 1 |
| Di Domenico, MG | 1 |
| De Robertis, E | 1 |
| Yen, YC | 1 |
| Lung, FW | 1 |
| Chong, MY | 1 |
| Scherer, J | 1 |
| Dobmeier, P | 1 |
| Kuhn, K | 1 |
| Schmaus, W | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Newman, M | 1 |
| Jampala, C | 1 |
| Chroni, E | 1 |
| Lekka, NP | 1 |
| Tsibri, E | 1 |
| Economou, A | 1 |
| Paschalis, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia[NCT00589914] | Phase 3 | 1,221 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The PANSS scale is used to assess the neuropsychiatric symptoms of schizophrenia. The 30-item PANSS scale provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items),and the general psychopathology subscale (16 items), each item rated on a scale of 1 (absent) to 7 (extreme). (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)
| Intervention | Scores on a scale (Mean) |
|---|---|
| R092670 | -18.6 |
| RISPERDAL CONSTA | -17.9 |
The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe). This scale permits a global evaluation of the patient's condition at a given time. A qualified rater administered the CGI-S. (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)]
| Intervention | Scores on a scale (Mean) |
|---|---|
| R092670 | -0.9 |
| RISPERDAL CONSTA | -0.9 |
The PSP scale is used to assess the degree of dysfunction a patient exhibits over a 7-day period within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The results of the assessment are converted to a numeric score. A score between 71 and 100 indicates a mild degree of difficulty; a score between 31 and 70 indicates a moderate degree of dysfunction, and a patient with a score of 30 or less has functioning so poor he or she requires intensive supervision. (NCT00589914)
Timeframe: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)
| Intervention | Scores on a scale (Mean) |
|---|---|
| R092670 | 8.5 |
| RISPERDAL CONSTA | 8.8 |
3 trials available for risperidone and Catatonic Rigidity
| Article | Year |
|---|---|
Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
Topics: Adult; Age of Onset; Antipsychotic Agents; Delayed-Action Preparations; Diagnostic and Statistical M | 2014 |
Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Topics: Adult; Blood Pressure; Case-Control Studies; Dopamine Antagonists; Dose-Response Relationship, Drug; | 2004 |
[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Cross-Sectio | 2004 |
6 other studies available for risperidone and Catatonic Rigidity
| Article | Year |
|---|---|
Challenges in the management of delirium: a case of augmentation with donepezil following inadequate response and adverse effects with risperidone.
Topics: Anticholinergic Syndrome; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Burns; Cholinestera | 2015 |
Extrapyramidal side effects: could you identify them in the emergency department?
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dopamine Antagonists; Dyskinesi | 2009 |
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].
Topics: Acute Kidney Injury; Adult; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Fever; H | 2003 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Atypical neuroleptic malignant syndrome associated with risperidone treatment.
Topics: Antipsychotic Agents; Bipolar Disorder; Female; Humans; Middle Aged; Muscle Rigidity; Neuroleptic Ma | 1997 |
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hepatolenticular Degeneratio | 2001 |